Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
TALS Talaris Therapeutics
1.720
+0.090+5.52%
Post Mkt Price
1.7200.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
51.82% 19.82M 66.55% 18.42M 104.49% 18.41M 109.43% 47.51M
Selling and administrative expenses
24.99% 4.84M 49.93% 5.23M 66.26% 4.22M 79.07% 13.26M
-General and administrative expense
24.99% 4.84M 49.93% 5.23M 66.26% 4.22M 79.07% 13.26M
Research and development costs
63.14% 14.98M 74.20% 13.19M 119.48% 14.2M 124.15% 34.25M
Operating profit
-51.82% -19.82M -66.55% -18.42M -104.49% -18.41M -109.43% -47.51M
Net non-operating interest income expense
600.00% 812K 208.14% 319K 152.72% 155K -1,317.39% -326K
Total other finance cost
-600.00% -812K -208.14% -319K -152.72% -155K 1,317.39% 326K
Other net income (expense)
Income before tax
-46.91% -19.01M -59.41% -18.1M -96.35% -18.26M -110.65% -47.83M
Income tax
Net income
-46.91% -19.01M -59.41% -18.1M -96.35% -18.26M -110.65% -47.83M
Net income continuous Operations
-46.91% -19.01M -59.41% -18.1M -96.35% -18.26M -110.65% -47.83M
Minority interest income
Net income attributable to the parent company
-46.91% -19.01M -59.41% -18.1M -96.35% -18.26M -110.65% -47.83M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-46.91% -19.01M -59.41% -18.1M -96.35% -18.26M -110.65% -47.83M
Basic earnings per share
-43.75% -0.46 -7.32% -0.44 -99.55% -0.45 -53.27% -1.64
Diluted earnings per share
-43.75% -0.46 -7.32% -0.44 -99.55% -0.45 -53.27% -1.64
Dividend per share
Currency Unit
USDUSDUSDUSD
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Talaris Therapeutics, Inc. engages in cell therapy. It develops methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its technologies are used to treat inherited metabolic enzyme disorders, red blood cell disorders to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Louisville, KY.
CEO: Mr. Scott Requadt
Market: NASDAQ
Listing Date: 05/07/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist